Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillermo Garcia

Showing results (231-240 of 1,188) with videos related to

Pageof 119
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 16, 2013
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failureElias Jabbour, Hagop Kantarjian, Hady Ghanem, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2015
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignanciesTalha Badar, Jorge E Cortes, Farhad Ravandi, et al.
Waste Management (New York, N.Y.)|January 9, 2024
Environmental and economic assessment of biodegradable and compostable alternatives for plastic materials in greenhousesJacob Thrän, Guillermo Garcia-Garcia, Carlos Parra-López, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 11, 2021
Oral Azacitidine (CC-486) for the Treatment of Myeloid MalignanciesGuillermo Garcia-Manero, Hartmut Döhner, Andrew H Wei, et al.
Blood|March 21, 2012
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experienceElias Jabbour, Jorge Cortes, Aziz Nazha, et al.
Journal of Thoracic Disease|July 26, 2017
Mitral valve repair and subvalvular intervention for secondary mitral regurgitation: a systematic review and meta-analysis of randomized controlled and propensity matched studiesChristos G Mihos, Steve Xydas, Evin Yucel, et al.
Leukemia Research|May 4, 2004
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literatureApostolia-Maria Tsimberidou, Jorge Medina, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2012
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II studyAsifa Malik, Mahran Shoukier, Guillermo Garcia-Manero, et al.
Blood|January 9, 2007
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemiaElias Jabbour, Susan O'Brien, Hagop Kantarjian, et al.
Leukemia Research|November 18, 2008
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation statusNitin Jain, Jorge Cortes, Alfonso Quintás-Cardama, et al.
Pageof 119

Showing results (231-240 of 1,188) with videos related to

Sort By:
Pageof 119
Clinical Lymphoma, Myeloma & Leukemia|January 16, 2013
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failureElias Jabbour, Hagop Kantarjian, Hady Ghanem, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2015
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignanciesTalha Badar, Jorge E Cortes, Farhad Ravandi, et al.
Waste Management (New York, N.Y.)|January 9, 2024
Environmental and economic assessment of biodegradable and compostable alternatives for plastic materials in greenhousesJacob Thrän, Guillermo Garcia-Garcia, Carlos Parra-López, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 11, 2021
Oral Azacitidine (CC-486) for the Treatment of Myeloid MalignanciesGuillermo Garcia-Manero, Hartmut Döhner, Andrew H Wei, et al.
Blood|March 21, 2012
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experienceElias Jabbour, Jorge Cortes, Aziz Nazha, et al.
Journal of Thoracic Disease|July 26, 2017
Mitral valve repair and subvalvular intervention for secondary mitral regurgitation: a systematic review and meta-analysis of randomized controlled and propensity matched studiesChristos G Mihos, Steve Xydas, Evin Yucel, et al.
Leukemia Research|May 4, 2004
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literatureApostolia-Maria Tsimberidou, Jorge Medina, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2012
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II studyAsifa Malik, Mahran Shoukier, Guillermo Garcia-Manero, et al.
Blood|January 9, 2007
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemiaElias Jabbour, Susan O'Brien, Hagop Kantarjian, et al.
Leukemia Research|November 18, 2008
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation statusNitin Jain, Jorge Cortes, Alfonso Quintás-Cardama, et al.
Pageof 119